Rare Diseases
Cost-Utility Analysis (CUA) of Belimumab (BEL) in the Treatment of Adult Patients with Active, Autoantibody-Positive Systemic Lupus Erythematosus (SLE), Walczak J, Kopel J, Sołtys E, Dziurda D, Value in Health 2013, 16(7): A385. Poster:
Cost-Effectiveness Analysis of Cysteamine in the Treatment of Patients with Cystinosis – a Rare Disease, Walczak J, Stelmachowski J, Obrzut G, Hubert A, Value in Health, 2013, 16(7): A383. Poster:
Cost-Effectiveness Analysis of Cysteamine in the Treatment of Patients with Cystinosis – a Rare Disease, Garbacka M, Małysiak S, Zawieja J, Walczak J, Bulica P. Źródło.
Analiza ekonomiczna romiplostymu w leczeniu dorosłych pacjentów z przewlekłą pierwotną małopłytkowością immunologiczną w Polsce, Garbacka M, Zawieja J, Walczak J, Bulica P. 2012 Źródło.
Przegląd systematyczny efektywności i bezpieczeństwa romiplostymu w leczeniu dorosłych pacjentów z przewlekłą pierwotną małopłytkowością immunologiczną (ITP), Jarosz J, Lipińska M, Bulica P. 2012 Źródło.
Przegląd systematyczny efektywności klinicznej romiplostymu w leczeniu dorosłych pacjentów z przewlekłą pierwotną małopłytkowością immunologiczną (ITP), Kowalska M, Jarosz J, Lipińska M, Walczak J, Bulica P. 2012 Źródło.
Jakościowy przegląd badań z użyciem bezwodnej betainy (Cystadane®) w leczeniu homocystynurii, Walczak J, Chmiel M, Zapalska A, Szczerbińska A. Farmakoekonomika, 2009, 13(3-4):3-4.
Analiza ekonomiczna betainy (preparat Cystadane®) w leczeniu pacjentów z homocystynurią, Nogas G, Walczak J, Kopel J, Labak-Klimasara M, Pieniążek I, Pawlik D. Farmakoekonomika, 2009, 13(3-4):3-4.
Dermatology
Systematic review of the efficacy and safety of imiquimod 5% cream for the treatment of actinic keratoses, Walczak J, Nogas G, Chmiel M, Kowalska M. Value Health. 2009;12(7):A452-A453. Poster:
Cost-effectiveness analysis of imiquimod versus no treatment in Actinic Keratoses, Walczak J, Nogas G, Dybek-Karpiuk A, Kloc K, Labak M, Pawlik D. Value Health. 2009;12(7):A456. Poster:
Endocrinology
The budget impact analysis of vildagliptin in type 2 diabetes in Poland, Walczak J, Nogas G, Gebus E, Pawlik D, Pacocha K. Value Health. 2009;12(7):A403-A404. Poster:
The cost-effectiveness analysis of vidalgliptin in type 2 diabetes in Poland, Walczak J, Nogas G, Gebus E, Pawlik D, Pacocha K. Value Health. 2009;12(7):A406. Poster:
Systematic review of the efficacy and safety of vildagliptin for type 2 diabetes mellitus, Walczak J, Nogas G, Organa M, Przada P, Potoczny R. Value Health. 2009;12(7):A402. Poster:
The cost-effectiveness of insulin glulisine in type 2 diabetes in Poland, Walczak J, Dardzinski W, Kusy M, Lis J, Nogas G. Value Health. 2008;11(3):A226. Poster:
The cost-utility and budget impact analysis of sitagliptin (januvia®) in type 2 diabetes in Poland, Walczak J, Malczak I, Panasiuk A, Pawlik D, Lasota K, Stelmachowski J, Nogas G. Value Health. 2008;11(6):A500. Poster:
The Budget Impact of Apidra(r) (insulin glulisine) reimbursement in Poland, Walczak J, Mucha J, Augustynska J, Gierczynski J, Nogas G. Value in Health, 2008, 11(3): A222. Poster:
Comparative cost-utility analysis of long-acting insulin analogue (insulin detemir) and NPH insulin for the treatment of type 1 and type 2 diabetes and the budget impact analysis of insulin analogue reimbursement in Poland, Walczak J, Pawlik D, Jasinska A, Garbacka M, Kedzior J, Fundament T, Malczak I, Dardzinski W, Skrzekowska-Baran I, Czech M, Nogas G. Value Health. 2008;11(6):A500. Poster:
The Budget Impact of Apidra (insulin glulisine) reimbursement in Poland, Walczak J, Mucha J, Augustyńska J, Gierczynski J, Nogas G. Źródło.
Gynaecology
Costs and resource use related to the induction of labour in 5 European countries – data collected via questionnaires during misoprostol vaginal insert pharmacoeconomic model development, Bierut A, Dowgiallo-Smolarczyk 1, Pacocha K, Pieniążek I, Stelmachowski J, Walczak J, Sobkowski M, Opala T, Baev O. PTFE 2014.
Misoprostol Vaginal Insert Pharmacoeconomic Model for 5 European Countries, Walczak J, Bierut A, Dowgiallo J, Pacocha K, Pieniazek I, Stelmachowski J, Opala T, Sobkowski M, Baev O, Value in Health 2014, Vol. 17, Issue 7, A508. Poster:
Interventions to reduce or prevent obesity in pregnant women: a systematic review, Thangaratinam S, Rogozinska E, Jolly K, Glinkowski S, Duda W, Borowiack E, Roseboom T, Tomlinson J, Walczak J, Kunz R, Mol BW, Coomarasamy A, Khan KS. Health Technol Assess. 2012;16(31):iii-191..
Effects of interventions in pregnancy on maternal weight and obstetric outcomes: meta-analysis of randomised evidence, Thangaratinam S, Rogozińska E, Jolly K, Glinkowski S, Roseboom T, Tomlinson JW, Kunz R, Mol BW, Khan KS. BMJ. 2012;344:e2088..
Secondary prevention of spontaneous preterm birth. Evidence quality assessment of effectiveness, Walczak J. .
Systematic review of the efficacy and safety of imiquimod 5% cream for the treatment of external genital warts, Walczak J, Nogas G, Chmiel M, Kowalska M. Value in Health 2014, Vol. 17, Issue 7, A508. Poster:
Cost-effectiveness analysis of imiquimod versus podophyllotoxin in treatment of genital/perianal warts in Poland, Walczak J, Nogas G, Dybek-Karpiuk A, Kloc K, Labak M, Pawlik D. Value Health. 2009;12(7):A426. Poster:
Carbetocin in prevention of uterine atony following delivery by cesarean section in population who experienced postpartum hemorrhage: costs in Polish setting, Pacocha K, Pieniazek I, Sobkowski M, Celewicz Z, Kalinka J, Szymanowski K, Serafin M, Szpak K, Grzymala-Figura A, Walczak J, Bierut A, Izbicki W, ISPOR 21st Annual International Meeting, Washington DC, USA, May, 2016; Value in Health 19(2016) A1-A318. Poster:
Misoprostol vaginal insert in labor induction: A Cost–Consequences Model for 5 European Countries—An Economic Evaluation Supported with Literature Review and Retrospective Data Collection, A. Bierut, J. Dowgiałło-Smolarczyk, I. Pieniążek, J. Stelmachowski, K. Pacocha, M. Sobkowski O. R. Baev, J. Walczak Advances in Therapy, 22 August 2016, pp 1-16, doi:10.1007/s12325-016-0397-3.
Costs of the use of carbetocin in the prevention of uterine atony following delivery of the infant by Caesarean section — retrospective multicenter study, M. Sobkowski, Z. Celewicz, J. Kalinka, K. Szymanowski, M. Serafin, K. Śmieja, A. Grzymała-Figura, K. Pacocha, I. Pieniążek, J. Walczak, A. Żyła, A. Bierut, Ginekol Pol 2016;87(9):621-628..
Haematology
Clinical Effectiveness Analysis of Deferasirox for the Treatment of Iron Overload Due to Frequent Blood Transfusions, Walczak J, Lipińska M, Jarosz J, Moczyński W, Ślązak B, Laczewski T, Value in Health 2013, 16(7): A377-A378. Poster:
The Budget Impact Analysis of Deferasirox for the Treatment of Iron Overload Due to Frequent Blood Transfusions in Children and Adolescents (Age ≤18 Years), Walczak J, Obrzut G, Sołtys E, Laczewski T, Value in Health 2013, 16(7): A379. Poster:
Cost-Utility Analysis of Deferasirox, for the Treatment of Iron Overload Due to Frequent Blood Transfusions in the Children and Adolescents., Walczak J, Sołtys E, Obrzut G, Laczewski T, Value in Health 2013, 16(7): A385. Poster:
Oncology
Cost-Utility Analysis of Deferasirox, for the Treatment of Iron Overload Due to Frequent Blood Transfusions in the Children and Adolescents., Walczak J, Sołtys E, Obrzut G, Laczewski T, Value in Health 2013, 16(7): A385. Poster:
Bortezomib-based regimens used as induction in newly diagnosed multiple myeloma (NDMM) patients eligible for stem cell transplantation (SCT): the cost-utility analysis., Mucha J, Walczak J, Tronczyński K , Skrzekowska-Baran I, Value in Health 2014, Vol. 17, Issue 3, A229. Poster:
Prototype Model in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): A Tool to Position New Treatments in the Patient Pathway?, Karcher H, Dinet J, Amzal B, Marteau F, Obrzut G, Pieniazek I, Brulais S, Gabriel S, Value in Health 2013, 16(7): A593. Poster:
Positron emission tomography/computerised tomography imaging in detecting and managing recurrent cervical cancer: systematic review of evidence, elicitation of subjective probabilities and economic modeling., Meads C, Auguste P, Davenport C, Małysiak S, Sundar S, Kowalska M, Zapalska A, Guest P, Thangaratinam S, Martin-Hirsch P, Borowiack E, Barton P, Roberts T, Khan K. HTA, 2013;17(12):1-323. Poster:
Sentinel lymph node (SLN) status in vulval cancer: Systematic quantitative reviews and decision analytic model-based economic evaluation, Meads C, Sutton A, Małysiak S, Kowalska M, Zapalska A, Rogozińska E, Baldwin P, Rosenthal A, Ganesan R, Borowiack E, Barton P, Roberts T, Sundar S and Khan K. HTA 2013; 17(60).
Clinical effectiveness and cost-utility analysis of sunitinib for the treatment of pancreatic neuroendocrine tumors., Walczak J, Garbacka M, Jarosz J, Lipińska M, Zawieja J, Prząda-Machno, Kroc J, Journal of Health Policy Outcomes Research, 2012, 2, 48-63
Treatment of well-differentiated pancreatic neuroendocrine tumors with sunitinib in patients with disease progression: cost-utility and cost-effectiveness analysis, Walczak J, Garbacka M, Zawieja J, Prząda-Machno P, Kroc J. Value Health. 2012;15(7):A426. Poster:
Transparency of drug reimbursement in Poland-oncology, Kujawska A, Nogas G. Value Health. 2010;13(7):A278
Budget impact analysis of docetaxel reimbursement in induction therapy of locally advanced head and neck squamous cell carcinoma in Poland, Walczak J, Lasota K, Malczak I, Pawlik D, Semeniuk A, Simon A, Bryl M, Gierczynski J, Nogas G. Value Health. 2009;12(3):A40. Poster:
Cost-effectivenes analysis of docetaxel versus standard regimen as the induction chemotherapy of locally advanced head and neck squamous cell carcinoma in Poland, Walczak J, Lasota K, Malczak I, Pawlik D, Semeniuk A, Simon A, Bryl M, Lis J, Nogas G. Value Health. 2009;12(3):A43. Poster:
Systematic review of the efficacy and safety of imiquimod 5% cream for the treatment of superficial basal cell carcinoma, Walczak J, Nogas G, Chmiel M, Kowalska M. Value Health. 2009;12(7):A259. Poster:
Cost-effectiveness analysis of imiquimod versus no treatment in patients with superficial basal cell carcinoma and contraindication to surgical intervention/cryotherapy, Walczak J, Nogas G, Dybek-Karpiuk A, Kloc K, Labak M, Pawlik D, Value Health 2009;12(7):A275-A276. Poster:
Budget impact analysis of the continuation of Docetaxel reimbursement in the neoadjuvant therapy of locally advanced breast cancer and palliative therapy of metastatic breast cancer in Poland, Walczak J, Gebus E, Lasota K, Semeniuk A, Malczak I, Pawlik D, Lis J, Glasek M, Nogas G. Value Health. 2008, 11 (6), A46. Poster:
Cost utility analysis of decotaxel versus standard regimen in the neoadjuvant therapy of locally advanced breast cancer in Poland, Walczak J, Gebus E, Lasota K, Semeniuk A, Pawlik D, Malczak I, Lis J, Glasek M, Nogas G. Źródło
Cost-effectiveness analysis of Docetaxel versus other regimens in the adjuvant therapy of early and locally advanced breast cancer in Poland, Walczak J, Pawlik D, Wojcik R, Kaczor M, Lis J, Nogas G. Value Health 2007;10(3):A12. Poster:
Budget Impact Analysis of Dasatynib In Treatment of Adult Patients With Philadelphia Chromosome Positive (Ph+) Acute Lymbphoblastic Leukemia (All) With Resistance or Intolerance to Prior Therapy In Poland, Mucha J, Stelmachowski J, Walczak J, Pieniazek I, Labak-Klimasara M, Obrzut G. Value in Health, 2015, Vol. 18, Issue 7, A663
Economic Evaluation of Dasatynib In Treatment of Adult Patients With Philadelphia Chromosome Positive (Ph+) Acute Lymbphoblastic Leukemia (All) With Resistance or Intolerance to Prior Therapy In Poland, Mucha J, Stelmachowski J, Walczak J, Pieniazek I, Obrzut G, Labak-Klimasara M. Value in Health, 2015, Vol. 18, Issue 7, A671–A672
Nivolumab (Opdivo®) in the treatment of advanced (unresectable or metastatic) melanoma in adults – economic analysis and recommendations for reimbursement according to the algorithm of assessment of novel oncological drugs in Poland, Mucha J, Walczak J, Pieniazek I, Labak-Klimasara M. PTFE, 2015
Nivolumab in the treatment of advanced (unresectable or metastatic) melanoma in adults – comparison with alternative technologies in Poland based on systematic review and statistical analysis, Ozga-Czarny I, Wiśniewska I, Walczak J, Pieniazek I, Labak-Klimasara M. PTFE, 2015
Comparing emerging drugs in metastatic Renal Cell Carcinoma (mRCC) without hazard ratios, Wiecek W, Karcher H, Nikodem M. ISPOR 18th Annual European Congress, Milan, Italy, November, 2015, The ISPOR Scientific Presentations Database
Assessment of quality and clinical significance of endpoints in cancer immunotherapy, Miernik K, Czarny-Ozga I, Walczak J. Journal of Health Policy Outcomes Research’ (JHPOR) 2015, Issue 2
Orthopedics
Assessment of clinical effectiveness of intrathecal baclofen in the treatment of spasticity – systematic literature review, Walczak J, Jóźwiak M, Chmiel M, Kowalska M. PJRR, 2012, 1(1): 24-31. Poster:
A cost-effectiveness analysis of programmable baclofen pump therapy in children with spastic cerebral palsy, Walczak J, Józwiak M, Jasinska A, Garbacka M, Obrzut G, Dardziński W. JHPOR. 2012;81-88
Metoda Kramera I Kellera w leczeniu deformacji koślawej paluchów / [Kramer’s and Keller’s methods in hallux valgus deformation treatment], Gądek A, Walczak J, Więcek R, Grzenia G. Przegl Lek. 2007;64(1):15-88
Economic model for purchasing of the different types of prosthesis used in primary THR and TKR In Poland, Niżankowski R, Łanda K, Podmokły A, Bała M, Plisko R, Łączyńska M, Walczak J, Kawalec P, Ryś P, Łyczakowska S. 6th Congress of the EFFORT, 2003, Finland, P6113; Poster session: General orthopaedics: 347
Wyniki leczenia przedniego nawykowego zwichnięcia stawu ramiennego metodą Bankarta / [Results of shoulder anterior instability treatment with Bankart procedure], Gądek A, Walczak J. Przegl Lek. 2002;59(7):499-501.
Ocena wyników klinicznych procedury wg. Girdlestone’a po endoprotezo plastyce stawów biodrowych / Clinical results evaluation of the Girdlestone’s procedure after hip arthrography, Golda W, Pawelec A, Walczak J. Ortop Traumatol Rehabil. 2001;3(1):68-70.
Psychiatry
Comparative analysis of the efficacy and safety of escitalopram with sertraline and venlafaxine in the treatment of major depressive disorder (MDD), Walczak J, Małysiak S, Rowińska M. Value Health. 2010;13(3):A107
Economic analysis of escitalopram (generic drug) in major depressive disorder (MDD), Walczak J, Nogas G, Garbacka M, Obrzut G, Pieniazek I. Value Health. 2010;13(3):A114 . Poster:
Escitalopram (generic drug) in major depressive disorder (MDD) – Budget impact analysis, Walczak J, Nogas G, Garbacka M, Obrzut G, Pieniazek I. Value Health. 2010;13(3):A109
Assessment of quality of life in patients with schizophrenia and their caregivers in selected Central and Eastern European countries: A literature review., Szkultecka-Dębek M, Walczak J, Augustyńska J, Miernik K, Stelmachowski J, Pieniążek I, Obrzut G, Pogroszewska A, Paulić G, Damir M, Antolić S, Tevcar R, Indrikson A, Aadamsoo K, Jankovic S, Pulay AJ, Rimay J, Varga M, Sulkova I, Verzun P. Journal of Health Policy Outcomes Research’ (JHPOR) 2015, Issue 1
Epidemiology and treatment guidelines of negative symptoms in Schizophrenia in Central and Eastern Europe: A literature Review., Szkultecka-Dębek M, Walczak J, Augustyńska J, Miernik K, Stelmachowski J, Pieniążek I, Obrzut G, Pogroszewska A, Paulić G, Damir M, Antolić S, Tevcar R, Indrikson A, Aadamsoo K, Jankovic S, Pulay AJ, Rimay J, Varga M, Sulkova I, Verzun P. Clinical Practise Epidemiology in Mental Health 2015, 11, 158-165 .
Schizophrenia and negative symptoms – burden of disease In seven Central and Eastern European (CEE) countries. Literature review and retrospective data collection, Szkultecka-Debek M, Walczak J, Augustynska J, Pieniazek I, Debowska G, Miernik K. project design and rationale, JHPOR 2013, 2
Schizophrenia and Negative Symptoms – Burden of the Disease in Seven Central and Eastern European (CEE) Countries: THE Results of the Literature Review, Walczak J, Augustyńska J, Miernik K, Stelmachowski J, Pieniazek I, Obrzut G, Pogroszewska A, Szkultecka-Debek M, Paulic G, Maric D, Anatolic S, Pecenak J, Tavcar R, Indrikson A, Jankovic S, Pulay AJ, Rimay J, Varga M, Sulkova I. Value in Health 2013, 16(7): A545-A546 . Poster:
Budget impact analysis of sertindole in the treatment of schizophrenia in Poland, Walczak J, Augustynska J, Soltys E, Nogas G. Value Health. 2010;13(7):A446-A447. Poster:
Cost-utility analysis (CUA) of sertindole in the treatment of schizophrenia in Poland in general population of schizophrenic patients and population of patients intolerant to at least one other antipsychotic agent: A five-year markov model., Walczak J, Stelmachowski J, Obrzut G, Nogas G. Value Health. 2010;13(7):A453 . Poster:
Cost-utility and budget impact of sertindole in the treatment of schizophrenia in Poland, Walczak J, Dardziński W, Pawlik D, Nogas G. Value Health. 2008;11(6):A583 . Poster:
Schizophrenia causes significant burden to patients and caregivers lives. Szkultecka-Dębek M, Miernik K, Stelmachowski J, Jakovljević M, Juki V, Aadamsoo K, Janno S, Bitter I, Tolna J, Jarema M, Jankovic S, Pecenak J, Vavrusova L, Tavčar R, Walczak J, Talbot D, Augustyńska J. Psychiatria Danubina, 2016; Vol. 28, No. 2, pp 104-110
Treatment patterns of schizophrenia based on the data from seven Central and Eastern European Countries Szkultecka-Dębek M, Miernik K, Stelmachowski J, Jakovljević M, Jukić V, Aadamsoo K, Janno S, Bitter I, Tolna J, Jarema M, Jankovic S, Pecenak J, Vavrusova L, Tavčar R, Walczak J, Talbot D, Augustyńska J. Psychiatr Danubina, 2016 Sep;28(3):234-242
Vaccines
Economic analysis of 2-dose varicella vaccination-comparison of the modeling results in the Polish and Hungarian environments Mészáros K, Dziurda D, Wepsiec K, Érsek K, Tóth E, Walczak J, Sauboin C, Chen Y-C. 31st Annual Meeting of the European Society for Paediatric infectious Diseases [ESPID] , Italy, 2013
Transplantation
Extracorporeal photopheresis for the treatment of patients with acute or chronic graft versus host disease (GVHD), refractory to corticosteroids – a systematic review Walczak J, Miernik K, Kuter I, Ussowicz M. Value Health. 2012;15(7):A345-A346
Economical aspects of the reimbursement of extracorporeal photopheresis (ECP) in treatment of patients with graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT) who are refractory to steroid treatment., Walczak J, Wepsiec K, Lemanski T, Zawieja J, Ussowicz M. Value Health. 2012;15(7):A349 . Poster:
Respiratory System
Clinical effectiveness of adjustable dosing single inhaler budesonide/formoterol for asthma and budget impact analysis, Kaczor M, Becla L, Wojcik R, Dardziński W, Walczak J, Nogas G. Value Health. 2006;9(6):A332 . Poster:
Urology
Budget Impact Analysis of Avodart (Dutasteride) in the treatment of Bening Prostatic Hyperplasia (BPH) in Poland, Dardziński W, Pawlik D, Walczak J, Wojcik R, Kaczor M, Nogas G, Glogowski C, Cel M. Value Health. 2006;9(6):A252 . Poster:
Cost-effectiveness of Dutasteride in the treatment of Benign Prostatic Hyperplasia (BPH), Kaczor M, Pawlik D, Becla L, Dardziński W, Jasinska A, Wojcik R, Walczak J, Nogas G, Cel M, Glogowski C, Zespol-Instytutu A. Value Health. 2006;9(6):A253-A254 . Poster:
Addiction
Naltrexone (50 mg) plus psychotherapy in alcohol-dependent patients: a meta-analysis of randomized controlled trials. Jarosz J, Miernik K, Wąchal M, Walczak J, Krumpl G. The American Journal of Drug and alcohol Abuse, 2013, 39(3):144-160
Clinical effectiveness analysis of naltrexone versus acamprosate and placebo in alcohol dependent patients treated with psychotherapy, Jarosz J, Miernik K, Wachal M, Walczak J. Value Health. 2011;14(3):A187-A188 . Poster:
Treatment of alcohol-dependent patients in Poland – is it cost-effective?, Walczak J, Gebus E, Pacocha K. 8th annual meeting HTAi, Rio de Janerio 2011, M-124, pp. 196 [678] . Poster:
Systematic review of the effectiveness of naltrexone vs acamprosate in the treatment of alcohol dependent patients who additionally undergo psychotherapy., Walczak J, Jarosz J, Miernik K, Wachal M. 8th annual meeting HTAi, Rio de Janerio 2011, M-063, pp. 165 [678] . Poster:
The budget impact analysis of naltrexone in the treatment of alcohol-dependent patients in Poland., Walczak J, Jarosz J, Miernik K, Wachal M. Value Health. 2011;14(3):A188-A189. Poster:
Systematic review of the efficacy and safety of varenicline for smoking cessation compared with placebo, nicotine replacement therapy or sustained-release bupropion., Walczak J, Nogas G, Czarny I, Baginski P, Borowiack E. Value Health. 2009;12(7):A298 . Poster:
The cost-effectiveness analysis of varenicline for smoking cessation in Poland., Walczak J, Nogas G, Dybek-Karpiuk A, Augustynska J, Stelmachowski J, Garbacka M, Obrzut G, Pawlik D. Value Health. 2009;12(7):A303 . Poster:
Nutrition
Comprehensive literature search and review of breast milk composition as preparatory work for the setting of dietary reference values for vitamins and minerals Jarosz J, Miernik K, Wąchal M, Walczak J, Krumpl G. LASER Analytica, EXTERNAL SCIENTIFIC REPORT, EFSA supporting publications 2014
Other
Use of botulinum toxin type A in Poland: systematic review and questionnaire survey. JShergill S, Miasek A, Borowiack M, Czarny-Ozga I, Moczynski W, Stelmachowski J, Slazak B, Wachal M. Eur J Hosp Pharm. 2013, 20(suppl 1): A123-A124
Economic analysis of enoxaparin in comparison with fondaparinux in the treatment of deep-vein thrombosis (DVT) Walczak J, Nogas G, Garbacka M, Pieniazek I, Lis J, Obrzut G. Value Health. 2010;13(3):A164
Esomeprazole versus other Proton-Pump Inhibitors (PPI): clinical and cost effectiveness analysis.,Kaczor M, Belca L, Pawlik D, Dardziński W, Walczak J, Nogas G, Wojcik R, Zespol-Instytutu A. Value Health. 2006;9(6):A242 . Poster:
Dexamethasone (Ozurdex) in the Treatment of Macular Oedema Following Retinal Vein Occlusion – Retrospective Study in Poland. Kubicka-Trząska A, Michalska-Małecka K, Dmitriew A, Dębicka A, Gajdzik_Gajdecka U, Adamczyk-Ludyga A, Ulińska M, Zalewski D, Lipińska M, Nikodem M, Romanowska-Dixon B. Okulistyka 1/2016 (ROK XIX), 83-89, ISSN 1505-2753
